Sign in
Not yet taking people in United StatesEarly phase 1

How morphine affects breathing in sleep, with or without sleep apnea

Tests morphine's effect on sleep breathing, with and without sleep apnea.

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Impacts of Opioids on Respiratory Drive During Sleep
Status
Not yet recruiting
Phase
Early phase 1
People taking part
26 people, planned
Started
1 Jul 2026
Expected to end
31 Jan 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Morphine p.o.
  • Placebo
Record updated
29 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults and adults with obstructive sleep apnea (pauses in breathing during sleep). It studies how morphine affects breathing during sleep.

Age
18 Years to 65 Years
Sex
All sexes can join.
Disease stage
Healthy group: AHI (breathing pauses per hour) < 5 events/hr on a lab sleep study within 3 months of enrollment. Sleep apnea group: AHI > 10 events/hr on a lab sleep study within 3 months; treated or untreated.
Earlier treatment
People cannot join if they take medicines that stimulate or slow breathing, such as other opioids at home, barbiturates or benzodiazepines. Also not SSRIs, SNRIs, TCAs, MAOIs, buproprion or trazodone.

Main reasons for not taking part

  • Other breathing or sleep disorders, such as central sleep apnea, COPD, asthma, narcolepsy or awake SaO2 < 92%.
  • Allergy to morphine, opioids, lidocaine or oxymetazoline.
  • Kidney or liver problems, unstable heart disease, epilepsy or seizures, or severe psychiatric illness.
  • Pregnancy or breastfeeding.
  • History of substance abuse, especially opioids.

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Healthy controls: Apnea Hypopnea Index (AHI) < 5 events/hr on in-laboratory PSG within 3 months of enrollment
  • OSA group: AHI > 10 events/hr on in-laboratory PSG within 3 months of enrollment; treated or untreated

Who cannot take part

  • Medications expected to stimulate or depress respiration (including other opioids taken at home, barbiturates, benzodiazepines, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid)
  • medications that interact with morphine, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), Monoamine oxidase inhibitors (MAOIs), and the atypical antidepressants buproprion and trazodone
  • Sleep disordered breathing or respiratory disorders (other than OSA in the OSA group), such as central sleep apnea (>50% of respiratory events scored as central), chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions
  • Other sleep disorders: periodic limb movements (periodic limb movement index > 20/hr), narcolepsy, or parasomnias
  • Any unstable major medical condition
  • History of allergy to lidocaine or oxymetazoline
  • allergy to morphine or opioids
  • chronic obstructive pulmonary disease, asthma, or other significant respiratory disorders
  • history of substance abuse, particularly opioid abuse, will be excluded to prevent potential misuse or relapse
  • recent head injury, brain tumors, or other conditions leading to increased intracranial pressure
  • unstable heart disease, particularly those with risk factors for or a history of heart rhythm disorders
  • epilepsy or a history of seizures, as morphine can lower the seizure threshold
  • severe psychiatric conditions, particularly those with a history of psychosis, as opioids can exacerbate these conditions
  • untreated or unstable endocrine disorders like adrenal insufficiency or thyroid dysfunction
  • Contraindications for morphine, including:
  • kidney or liver dysfunction, as this can affect the metabolism and excretion of morphine, leading to increased risk of toxicity
  • women who are pregnant or breastfeeding will be excluded due to potential risks to the fetus or infant
  • current use of central nervous system depressants
  • individuals with gastrointestinal obstruction. Constipation is not an exclusion criterion because morphine is only administered for one night

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Brigham and Women's HospitalBoston, United StatesContact: Nicole CalianeseNot yet recruiting

About the trial

What the trial wants to find out

The investigators are studying the impact that opioids have on breathing during sleep in healthy participants and those diagnosed with obstructive sleep apnea.

The 2 groups in the trial

  • MorphineExisting treatment, for comparison

    Treatment: Morphine p.o.

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Mechanisms of Opioid-induced Respiratory Depression (OIRD) During Sleep
Plain-language title
How morphine affects breathing in sleep, with or without sleep apneaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06854211, who can take part
Record updated
29 January 2026